Glenmark’s Ryaltris Nasal Spray Receives EC’s Approval as 1L Treatment for Allergic Rhinitis

 Glenmark’s Ryaltris Nasal Spray Receives EC’s Approval as 1L Treatment for Allergic Rhinitis

Glenmark’s Ryaltris Nasal Spray Receives EC’s Approval as 1L Treatment for Allergic Rhinitis

Shots:

  • Glenmark is concluding the final, national phase of its MAA process to enable launch of its innovative nasal spray, Ryaltris (olopatadine hydrochloride, 665mcg and mometasone furoate, 25mcg), in 17 countries in the EU
  • Menarini will lead the commercialization in France, Italy, Spain, and the Balkan region under its collaboration with Glenmark signed in 2020. Glenmark has also partnered with Hikma and Bausch Health for the commercialization of Ryaltris in the US and Canada respectively
  • Ryaltris is a novel fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients aged >12yrs.

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Wikipedia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post